Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD

Postgraduate Medicine
Himanshu UpadhyayaAlbert J Allen

Abstract

Adults with attention-deficit/hyperactivity disorder treated with atomoxetine were examined for time-to-onset and -resolution of common treatment-emergent adverse events (TEAEs) and male sexual dysfunction, and for changes in blood pressure (BP) and heart rate (HR) upon atomoxetine discontinuation. 12-week open-label atomoxetine (40-100 mg/day) was followed by 12-week double-blind maintenance treatment (atomoxetine 80 or 100 mg/day). Responders were then randomized to atomoxetine (n = 266) or placebo (n = 258) for 25-week randomized withdrawal. Examined were (1) median time-to-onset and -resolution of TEAEs during atomoxetine treatment, and (2) within group, visitwise mean changes for sitting HR, systolic BP, and diastolic BP for the postrandomization placebo group. Common adverse events (AEs) appeared early, within week 1 of atomoxetine treatment. Some AEs resolve relatively rapidly, whereas others have a more lingering course of resolution (including male sexual side effects); median resolution times were 3 - 53 days. BP and HR increases during atomoxetine treatment returned to baseline upon atomoxetine discontinuation. Atomoxetine is associated with common AEs, with 3- to 53-day median resolution times. ClincialTrials.gov - ...Continue Reading

References

May 20, 1998·The American Journal of Psychiatry·T SpencerL Seidman
Feb 7, 2001·The American Journal of Psychiatry·T E WilensA Parekh
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Jul 17, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joachim F WernickeJohn Heiligenstein
Jun 24, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·David MichelsonJoseph Biederman
Nov 15, 2006·Pediatrics·Jeffrey H NewcornUNKNOWN Atomoxetine Low-dose Study Group
May 2, 2008·Journal of Attention Disorders·Lenard A AdlerDavid Michelson
Oct 22, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·William KielbasaRobert Stratford
Jan 15, 2009·Journal of Clinical Psychopharmacology·Lenard A AdlerDouglas Kelsey
Sep 12, 2009·Journal of Clinical Psychopharmacology·Crystal N HolickJohn D Seeger
Sep 4, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gary Stiefel, Frank M C Besag
Nov 3, 2011·The New England Journal of Medicine·William O CooperWayne A Ray
Dec 14, 2011·JAMA : the Journal of the American Medical Association·Laurel A HabelJoe V Selby
Jan 9, 2013·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Samuele CorteseUNKNOWN European ADHD Guidelines Group
Jun 19, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Angelo CamporealeDouglas K Kelsey
Jan 18, 2014·The Journal of Clinical Psychiatry·Linda A WietechaJeffrey H Newcorn

❮ Previous
Next ❯

Citations

Apr 7, 2017·Therapeutic Advances in Drug Safety·Jose Martinez-RagaEloisa Carabal
Jul 16, 2021·Neuroscience and Biobehavioral Reviews·Mathias LudererAndreas Reif

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.